NEEDHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the second quarter ended June 30, 2025, and provided a corporate update.
Related Questions
How does Candel's valuation and forward priceâtoâsales ratio compare to other clinicalâstage biotech peers developing immunotherapies?
How will the reported Q2 2025 revenue and cash burn affect CADL's cash runway and need for additional financing?
What are the specific clinical trial milestones mentioned, and how likely are they to be achieved on schedule?
Did the company provide any updated guidance for Q3 2025 or fullâyear 2025 earnings, and how does that compare to consensus estimates?
Are there any new partnership or licensing agreements disclosed that could bring nonâdilutive capital or accelerate commercialization?
What is the composition of the recent share issuances or option exercises, and what dilution impact might that have on existing shareholders?
Did the earnings release mention any regulatory interactions (e.g., FDA meetings, IND submissions) that could materially affect the timeline for product approvals?
How does the sentiment score of 10 align with market expectations, and could this indicate a potential overâ or underâreaction in the stock price?
What is the current shortâinterest level on CADL, and could the news trigger short covering or increased shortâselling activity?
Are there any macroâeconomic or sectorâspecific trends (e.g., biotech funding environment, cancerâtherapy market demand) that could amplify or mitigate the impact of this release on CADL's stock?